These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27383301)

  • 1. Evidence for miR-17-92 and miR-134 gene cluster regulation of ovarian cancer drug resistance.
    Zhu H; Yang SY; Wang J; Wang L; Han SY
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2526-31. PubMed ID: 27383301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines.
    Kazmierczak D; Jopek K; Sterzynska K; Nowicki M; Rucinski M; Januchowski R
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.
    Brozovic A; Duran GE; Wang YC; Francisco EB; Sikic BI
    Mol Oncol; 2015 Oct; 9(8):1678-93. PubMed ID: 26025631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
    Shuang T; Wang M; Shi C; Zhou Y; Wang D
    FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.
    Huh JH; Kim TH; Kim K; Song JA; Jung YJ; Jeong JY; Lee MJ; Kim YK; Lee DH; An HJ
    Br J Cancer; 2013 Jul; 109(2):452-61. PubMed ID: 23807165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
    Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells.
    Miyamoto M; Sawada K; Nakamura K; Yoshimura A; Ishida K; Kobayashi M; Shimizu A; Yamamoto M; Kodama M; Hashimoto K; Kimura T
    Sci Rep; 2020 Oct; 10(1):16755. PubMed ID: 33028939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Significance of MicroRNAs Expression in Regulation of Extracellular Matrix and Other Drug Resistant Genes in Drug Resistant Ovarian Cancer Cell Lines.
    Kazmierczak D; Jopek K; Sterzynska K; Ginter-Matuszewska B; Nowicki M; Rucinski M; Januchowski R
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
    Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of microRNAs in drug-resistant ovarian cancer cells.
    Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
    Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
    Wang J; Ye C; Liu J; Hu Y
    Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
    Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
    EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel.
    Chen N; Chon HS; Xiong Y; Marchion DC; Judson PL; Hakam A; Gonzalez-Bosquet J; Permuth-Wey J; Wenham RM; Apte SM; Cheng JQ; Sellers TA; Lancaster JM
    Oncol Rep; 2014 Jan; 31(1):376-83. PubMed ID: 24220856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance.
    Li B; Chen H; Wu N; Zhang WJ; Shang LX
    Int J Gynecol Cancer; 2014 Oct; 24(8):1381-8. PubMed ID: 25248111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
    Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
    BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
    Kim YW; Kim EY; Jeon D; Liu JL; Kim HS; Choi JW; Ahn WS
    Drug Des Devel Ther; 2014; 8():293-314. PubMed ID: 24591819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
    van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
    Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK.
    Zou D; Wang D; Li R; Tang Y; Yuan L; Long X; Zhou Q
    Tumour Biol; 2015 Sep; 36(9):6725-32. PubMed ID: 25833695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
    Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
    Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.